Clinical trials: Tislelizumab
Non-Small Cell Lung Cancer
SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04）
This study was an open-label, multi-center, randomized phase III study to evaluate the efficacy and safety of SYS6010 combined with Enlonstobart versus Immunotherapy+ Platinum-based chemotherapy as First-Line treatment for…
- Trial name
- NCT07633873
- Testing
- SYS6010 injection, Enlonstobart injection, Tislelizumab injection
- Volunteers
- 500 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Colorectal Cancer
Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities
The FUTURE trial is a prospective, multicentre, exploratory, open-label phase II platform trial. Its goal is to evaluate the efficacy, feasibility and safety of futibatinib combined with immunotherapeutic, targeted or…
- Trial name
- FUTURE (NCT06722183)
- Testing
- Futibatinib orally administered, Tislelizumab (i.v. 200mg)
- Where
- 10 sites in Germany
- Volunteers
- 33 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Minimal Residual Disease, Adjuvant Chemotherapy
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
To find out if a combination of fruquintinib and tislelizumab can control CRC in patients who have received treatment for the disease but still have "positive" ctDNA tests for MRD (meaning there is evidence of MRD based on this…
- Conditions
- Minimal Residual Disease, Adjuvant Chemotherapy, Colorectal Cancer, Fruquintinib
- Trial name
- NCT07136077
- Testing
- Tislelizumab, Fruquintinib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Rectal Cancer
Modified Short-Course Radiotherapy Combined With Tislelizumab and CAPOX for pMMR/MSS Rectal Cancer
The goal of this clinical trial is to learn if node-sparing modified short-course radiotherapy combined with tislelizumab and CAPOX works to treat pMMR/MSS locally advanced mid-to-low rectal cancer.
- Trial name
- mRCATS (NCT07900061)
- Testing
- node-sparing modified short-course radiotherapy, standard short-course radiotherapy
- Volunteers
- 210 people
- Sponsor
- Sir Run Run Shaw Hospital
Breast Cancer
Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed
This Phase II study was designed to assess the efficacy and safety of the combination of PD-1 inhibitor, Tucidinostat (chidamide), a histone deacetylase inhibitor, and anlotinib in advanced breast cancer.
- Trial name
- NCT06547476
- Testing
- Tucidinostat (chidamide), PD-1 inhibitor (tislelizumab), anlotinib
- Volunteers
- 40 people
- Sponsor
- Guangdong Provincial People's Hospital
Classical Hodgkin Lymphoma
A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma
The primary objective of this study was to evaluate the efficacy of tislelizumab assessed by Independent Review Committee (IRC) in participants with relapsed or refractory classical Hodgkin lymphoma (cHL), as measured by Overall…
- Trial name
- NCT03209973
- Testing
- Tislelizumab
- Where
- 12 sites in China
- Volunteers
- 70 people
- Sponsor
- BeiGene
Esophageal Squamous Cell Carcinoma
A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)
This trial is a registrational Phase II/III, randomized, controlled, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in combination with tislelizumab ± 5-FU in patients with unresectable, locally…
- Trial name
- NCT07554456
- Testing
- BL-B01D1, Tislelizumab, 5-Fluorouracil
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Unresectable Stage III Non-small Cell Lung Cancer, Tislelizumab
Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC
The goal of this phase 2 trial is to evaluate the efficacy and safety of tislelizumab combined with intravenous chemotherapy and bronchial artery chemoembolization (BACE) as conversion therapy for patients with initially…
- Conditions
- Unresectable Stage III Non-small Cell Lung Cancer, Tislelizumab, Chemotherapy, Chemoembolization, Therapeutic
- Trial name
- BEACON-Lung (NCT07561983)
- Testing
- Tislelizumab, Intravenous Chemotherapy, Bronchial Artery Chemoembolization (BACE)
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Unresectable Hepatocellular Carcinoma, Oligometastatic Disease
Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC
The goal of this phase 2 prospective clinical trial is to learn about the efficacy and safety of stereotactic body radiation therapy (SBRT) plus immunotherapy and targeted therapy in patients with unresectable or oligometastatic…
- Trial name
- NCT05917431
- Testing
- SBRT plus tislelizumab and regorafenib
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Peking University Cancer Hospital & Institute
Intrahepatic Cholangiocarcinoma
TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma
The objective of this study is to evaluate the efficacy and safety of TACE combined with Tislelizumab in patients with advanced intrahepatic cholangiocarcinoma after progression on first-line systemic therapy.
- Trial name
- NCT04954781
- Testing
- Tislelizumab, TACE
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma (HCC)
Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma
This study is a single-arm prospective clinical trial that enrolled 94 patients with unresectable hepatocellular carcinoma(HCC) who received first-line treatment with tislelizumab combined with Huaier granule.
- Trial name
- NCT07413354
- Testing
- Tislelizumab plus Huaier granule
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Tongji Hospital
OligoProgressive Metastatic Disease, Hepatocellular Carcinoma (HCC)
Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC
This multicenter, prospective, randomized, controlled, open-label, two-arm Phase III clinical trial is designed to evaluate whether adding radiotherapy to oligoprogressive lesions while continuing first-line systemic therapy at…
- Conditions
- OligoProgressive Metastatic Disease, Hepatocellular Carcinoma (HCC), Radiotherapy, Systemic Therapy
- Trial name
- NCT06841172
- Testing
- radiotherapy, Systemic therapy (Continuation of current first-line systemic therapy), Systemic therapy (Early switch to second-line systemic therapy)
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Shandong Cancer Hospital and Institute
Hepatocellular Carcinoma Resectable
A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC
In order to improve the R0 resection rate, reduce distant metastasis, and lower postoperative recurrence, there is a growing exploration of surgical treatments for hepatocellular carcinoma (HCC), including preoperative…
- Trial name
- NCT06003673
- Testing
- neoadjuvant therapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Immune-related Adverse Event, Malignant Solid Tumors
The Effect of Serum Ferritin in irAE
This is a prospective clinical study to clarify serum ferritin as a biomarker for the diagnosis, differential diagnosis and prognosis of immune-related adverse event(irAE).
- Conditions
- Immune-related Adverse Event, Malignant Solid Tumors, Acute Leukemia, Serum Ferritin
- Trial name
- NCT06702566
- Testing
- PD-1 and PD-L1 inhibitor, Targeted drugs, chemotherapy drugs
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophagus Cancer, Chemoradiotherapy
Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer
Chemoradiotherapy（CRT） is the main treatment for esophageal cancer patients with recurrent desease，and checkpoint blockade (PD-1) have been shown to be effective in advanced esophageal cancer.
- Conditions
- Esophagus Cancer, Chemoradiotherapy, Oligometastatic Disease, Immunotherapy
- Trial name
- NCT04821765
- Testing
- PD-1 antibody, Chemoradiation, Albumin-Bound Paclitaxel
- Where
- 2 sites in China
- Volunteers
- 35 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
RAS Mutation, Advanced Solid Tumor
A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations
The purpose of this study is to test if the BG-85738 is safe and if it works in patients with advanced solid tumors with RAS mutations when it is given on its own and in combination.
- Conditions
- RAS Mutation, Advanced Solid Tumor, Metastatic Solid Tumor
- Trial name
- NCT07746141
- Testing
- BG-85738, Tislelizumab, Cetuximab
- Where
- 3 sites in Australia, New Zealand
- Volunteers
- 100 people
- Sponsor
- BeOne Medicines
Recurrent Nasopharyngeal Carcinoma, Unresectable Nasopharyngeal Carcinoma
Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma
This is an open-label, multi-center, phase II trial to evaluate the safety and efficacy of postponing or omitting re-irradiation after systemic therapy with tislelizumab and chemotherapy in patients with unresectable recurrent…
- Conditions
- Recurrent Nasopharyngeal Carcinoma, Unresectable Nasopharyngeal Carcinoma, Chemotherapy Effect, Immunotherapy
- Trial name
- RETICULA-NPC (NCT04921995)
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fudan University
Esophageal Squamous Cell Carcinoma (ESCC)
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
The purpose of this study is to evaluate the efficacy and safety of tislelizumab as first line treatment in combination with chemotherapy in participants with advanced unresectable/metastatic esophageal squamous cell carcinoma…
- Trial name
- NCT03783442
- Testing
- Cisplatin, Oxaliplatin, Fluorouracil (5-FU)
- Where
- 124 sites in United States, Australia and 14 more
- Volunteers
- 649 people
- Sponsor
- BeiGene
Advanced Non-small-cell Lung Cancer
Tislelizumab as Cross-line Treatment for Advanced NSCLC
This study is a single-arm, prospective, open phase II clinical study, exploring the efficacy and safety for advanced non-small cell lung cancer after progression of first-line Tislelizumab combined with chemotherapy and…
- Trial name
- NCT05192681
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Fujian Cancer Hospital
Primary Mediastinal Large B Cell Lymphoma, EBV-Positive DLBCL, Nos
Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL
The study is to investigate the safety and efficacy of Zanubrutinib combined with Tislelizumab in the treatment of relapsed/refractory primary mediastinal large B-cell lymphoma and Epstein-Barr Virus-positive diffuse large B-cell…
- Trial name
- NCT04705129
- Testing
- Zanubrutinib, Tislelizumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ruijin Hospital